In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Morphogen-IX Ltd.

http://morphogen-ix.com/

Latest From Morphogen-IX Ltd.

Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach

With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.

Deals Research and Development Strategies

Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model

In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.

M & A Financing

CIC Raises £150M To Reinforce Cambridge Ecosystem

Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.

United Kingdom Commercial

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register